DNX-2440 for Resectable Colorectal Liver Metastasis
Key facts
- Who runs it
- DNAtrix, Inc.
- Where
- Tampa, United StatesSee the site
- Trial code
- Status
- Suspended
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Started
- 15 Feb 2021
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- DNX-2440
- Record updated
- 9 April 2024
- Why it stopped
- DNAtrix management decision not based on study design, safety, or site performance.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male or female aged ≥ 18 years at time of consent
- Diagnosis of liver metastases from colorectal, breast, gastric, periampullary, melanoma, renal cell cancer, sarcoma, squamous cell carcinoma or gastrointestinal stromal tumor
- Multiple (≥ 2) liver tumors
- Candidate for curative-intent surgery
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Candidates eligible for targeted therapy, as per standard of care guidelines (and based on mutational status as indicated), must have completed therapy
- Preoperative chemotherapy is allowed
Who cannot take part
- Liver metastasis treated with > 12 cycles of systemic chemotherapy
- Condition that requires ongoing systemic immunosuppressive therapy
- Liver transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) or total bilirubin > 5x the upper limits of normal
- Recurrence of liver metastasis
- Diagnosis of neuroendocrine tumor liver metastasis
- Evidence of inadequate organ function based on lab parameters
- Males or females who refuse to use a double-barrier form of birth control during the study and for up to 6 months after injection with DNX-2440
Where in United States
- H. Lee Moffitt Cancer Center and Research Institute, IncTampa, United States
About the trial
What the trial wants to find out
The purpose of this study is to test an experimental oncolytic adenovirus called DNX-2440 in patients with resectable multifocal (≥ 2 lesions) liver metastasis, who are scheduled to have curative-intent liver resection surgery. Up to 18 patients will receive two sequential intra-tumoral injections of DNX-2440 into a metastatic liver tumor prior to surgery for liver resection, to evaluate safety and biological endpoints across 3 dose levels (dose escalation). Upon conclusion of the dose-escalation phase, the selected safe and biologically appropriate dose will be administered using the same schema for an additional 12 patients with colorectal cancer liver metastasis (expansion cohort) using established biologic endpoints.
The 3 groups in the trial
- Dose-level 1Treatment being tested
The dose-level 1 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
Treatment: DNX-2440
- Dose-level 2Treatment being tested
The dose-level 2 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
Treatment: DNX-2440
- Dose-level 3Treatment being tested
The dose-level 3 arm will use a 3+3 design. A single dose of DNX-2440 will be delivered via intra-tumoral injection at Visit 1 and at Visit 3 (2 administrations in total) approximately 14 days apart.
Treatment: DNX-2440
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver Metastasis
- Record updated
- 9 April 2024